The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
12
11
2020
accepted:
29
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Onchocerciasis ("river blindness") can cause severe morbidity, including vision loss and various skin manifestations, and is targeted for elimination using ivermectin mass drug administration (MDA). We calculated the number of people with Onchocerca volvulus infection and onchocercal skin and eye disease as well as disability-adjusted life years (DALYs) lost from 1990 through to 2030 in areas formerly covered by the African Programme for Onchocerciasis Control. Per MDA implementation unit, we collated data on the pre-control distribution of microfilariae (mf) prevalence and the history of control. Next, we predicted trends in infection and morbidity over time using the ONCHOSIM simulation model. DALY estimates were calculated using disability weights from the Global Burden of Disease Study. In 1990, prior to MDA implementation, the total population at risk was 79.8 million with 26.0 million (32.5%) mf-positive individuals, of whom 17.5 million (21.9%) had some form of onchocercal skin or eye disease (2.5 million DALYs lost). By 2030, the total population was predicted to increase to 236.1 million, while the number of mf-positive cases (about 6.8 million, 2.9%), people with skin or eye morbidity (4.2 million, 1.8%), and DALYs lost (0.7 million) were predicted to decline. MDA has had a remarkable impact on the onchocerciasis burden in countries previously under the APOC mandate. In the few countries where we predict continued transmission between now and 2030, intensified MDA could be combined with local vector control efforts, or the introduction of new drugs for mopping up residual cases of infection and morbidity.
Sections du résumé
BACKGROUND
Onchocerciasis ("river blindness") can cause severe morbidity, including vision loss and various skin manifestations, and is targeted for elimination using ivermectin mass drug administration (MDA). We calculated the number of people with Onchocerca volvulus infection and onchocercal skin and eye disease as well as disability-adjusted life years (DALYs) lost from 1990 through to 2030 in areas formerly covered by the African Programme for Onchocerciasis Control.
METHODS
Per MDA implementation unit, we collated data on the pre-control distribution of microfilariae (mf) prevalence and the history of control. Next, we predicted trends in infection and morbidity over time using the ONCHOSIM simulation model. DALY estimates were calculated using disability weights from the Global Burden of Disease Study.
RESULTS
In 1990, prior to MDA implementation, the total population at risk was 79.8 million with 26.0 million (32.5%) mf-positive individuals, of whom 17.5 million (21.9%) had some form of onchocercal skin or eye disease (2.5 million DALYs lost). By 2030, the total population was predicted to increase to 236.1 million, while the number of mf-positive cases (about 6.8 million, 2.9%), people with skin or eye morbidity (4.2 million, 1.8%), and DALYs lost (0.7 million) were predicted to decline.
CONCLUSIONS
MDA has had a remarkable impact on the onchocerciasis burden in countries previously under the APOC mandate. In the few countries where we predict continued transmission between now and 2030, intensified MDA could be combined with local vector control efforts, or the introduction of new drugs for mopping up residual cases of infection and morbidity.
Identifiants
pubmed: 34310602
doi: 10.1371/journal.pntd.0009604
pii: PNTD-D-20-01989
pmc: PMC8312930
doi:
Substances chimiques
Antiparasitic Agents
0
Ivermectin
70288-86-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009604Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
PLoS Negl Trop Dis. 2013;7(1):e2032
pubmed: 23383355
Parasitology. 1995 May;110 ( Pt 4):409-27
pubmed: 7753582
Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):269-280
pubmed: 33515042
PLoS Negl Trop Dis. 2018 Oct 8;12(10):e0006624
pubmed: 30296264
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S29-39
pubmed: 12081248
PLoS Negl Trop Dis. 2016 Jan 15;10(1):e0004328
pubmed: 26771545
Ann Trop Med Parasitol. 2002 Apr;96(3):283-96
pubmed: 12061975
Popul Health Metr. 2006 Apr 18;4:4
pubmed: 16620383
J Infect Dev Ctries. 2020 Jun 29;14(6.1):28S-35S
pubmed: 32614793
Popul Health Metr. 2011 Apr 24;9:10
pubmed: 21513572
PLoS Negl Trop Dis. 2017 Mar 29;11(3):e0005489
pubmed: 28355223
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
PLoS Negl Trop Dis. 2009 Jun 16;3(6):e461
pubmed: 19529767
Infect Dis Poverty. 2016 Jun 27;5(1):66
pubmed: 27349645
PLoS Negl Trop Dis. 2018 May 3;12(5):e0006471
pubmed: 29723238
Bull World Health Organ. 1995;73(4):495-506
pubmed: 7554022
PLoS Negl Trop Dis. 2015 Sep 24;9(9):e0004051
pubmed: 26401658
Comput Methods Programs Biomed. 1990 Jan;31(1):43-56
pubmed: 2311368
Infect Dis Poverty. 2018 Sep 19;7(1):101
pubmed: 30253788
J R Soc Promot Health. 2004 May;124(3):134-6
pubmed: 15195454
Clin Infect Dis. 2020 May 23;70(11):2281-2289
pubmed: 31304961
Acta Leiden. 1990;59(1-2):387-98
pubmed: 2378221
Parasit Vectors. 2015 Oct 22;8:552
pubmed: 26489937
PLoS Negl Trop Dis. 2017 Jul 14;11(7):e0005732
pubmed: 28708828
Acta Trop. 2009 Sep;111(3):211-8
pubmed: 19619686
Int J Qual Stud Health Well-being. 2011;6(2):
pubmed: 21637349
PLoS Negl Trop Dis. 2021 Jun 11;15(6):e0009489
pubmed: 34115752
PLoS Negl Trop Dis. 2016 Jul 22;10(7):e0004829
pubmed: 27448085
PLoS Negl Trop Dis. 2016 Jan 14;10(1):e0004358
pubmed: 26766287
Acta Trop. 2013 Jun;126(3):218-21
pubmed: 23458325
PLoS Negl Trop Dis. 2015 Apr 10;9(4):e0003664
pubmed: 25860569
PLoS Negl Trop Dis. 2013;7(3):e2147
pubmed: 23556028
Int Health. 2018 Mar 1;10(suppl_1):i79-i88
pubmed: 29471335
Ann Trop Med Parasitol. 2002 Mar;96(2):181-9
pubmed: 12080979
Clin Microbiol Rev. 2002 Oct;15(4):595-612
pubmed: 12364371
Parasit Vectors. 2014 Jul 22;7:326
pubmed: 25053392
Bull World Health Organ. 1981;59(5):773-6
pubmed: 6976238
PLoS Negl Trop Dis. 2013 Apr 11;7(4):e2168
pubmed: 23593528
J Parasitol Res. 2012;2012:748540
pubmed: 22970347
PLoS Negl Trop Dis. 2018 Aug 27;12(8):e0006702
pubmed: 30148838
Bull World Health Organ. 1991;69(2):169-78
pubmed: 1860147
Postgrad Med J. 2010 Oct;86(1020):573-7
pubmed: 20971709
Popul Health Metr. 2006 Oct 31;4:13
pubmed: 17076901
Popul Health Metr. 2006 Apr 10;4:1
pubmed: 16606448
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Clin Exp Ophthalmol. 2017 Apr;45(3):217-220
pubmed: 27862844